Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
View Top Employees from OsivaxWebsite | http://www.osivax.com/ |
Revenue | $6.4 million |
Funding | $15.3 million |
Employees | 53 (34 on RocketReach) |
Founded | 2017 |
Address | 70, Rue Saint-Jean-de-Dieu, Lyon, Auvergne-Rhône-Alpes 69007, FR |
Phone | +33 9 70 30 13 80 |
Fax | +33 4 74 26 15 78 |
Technologies |
JavaScript,
HTML,
PHP
+19 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Clinical Trials, Health Care |
Web Rank | 17 Million |
Keywords | Osivax, Fergal Hill |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 325414 Companies, NAICS Code 3254 Companies |
Looking for a particular Osivax employee's phone or email?
The Osivax annual revenue was $6.4 million in 2024.
34 people are employed at Osivax.
Osivax is based in Lyon, Auvergne-Rhône-Alpes.
The NAICS codes for Osivax are [32541, 325, 32, 325414, 3254].
The SIC codes for Osivax are [28, 283].